CompletedPhase 1NCT01069471
Safety and Reactogenicity of Bioconjugate Vaccine to Prevent Shigella
Studying Shigellosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- GlycoVaxyn AG
- Principal Investigator
- Christoph Hatz, Prof. Dr.Institute of Social and Preventive Medicine
- Intervention
- Shigella vaccine(biological)
- Enrollment
- 40 enrolled
- Eligibility
- 18-50 years · All sexes
- Timeline
- 2010 – 2010
Study locations (1)
- Institute of Social and Preventive Medicine, Zurich, Switzerland
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01069471 on ClinicalTrials.govOther trials for Shigellosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07433426The Impact of Shigellosis and Recommended Treatment in ChildrenJohns Hopkins Bloomberg School of Public Health
- RECRUITINGPHASE1NCT05959616Shigella Sonnei 53G Human Infection Study in Kenyan AdultsUniversity of Oxford
- RECRUITINGPHASE2NCT06615375A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate VaccineLimmaTech Biologics AG
- RECRUITINGPHASE1NCT05961059InvaplexAR-Detox and DmLT Adjuvant in the Netherlands and ZambiaLeiden University Medical Center
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05182749Safety and Efficacy of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of ShigellosisIntralytix, Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT05121974Tebipenem Trial in Children With ShigellosisInternational Centre for Diarrhoeal Disease Research, Bangladesh